Phase 1 trial of ACT-017 for the treatment of Acute Ischemic Stroke
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs ACT 017 (Primary)
- Indications Stroke
- Focus Adverse reactions; First in man
- 19 May 2017 According to an Acticor Biotech media release, the company is planning to initiate this trial in October 2017 and to end in January 2018.
- 09 Feb 2017 New trial record
- 07 Feb 2017 According to an Acticor Biotech media release, company should start its Phase I 6 months earlier than originally planned because of encouraging pre-clinical results and positive regulatory meetings.The first subject could thus be scheduled for early Q4 2017.